Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22103175 | 0.78 | LTA4H (0.46) | — | |
| Hydrochloric Acid SCHEMBL22090384 | 0.77 | LTA4H (0.44) | — | |
| Hydrochloric Acid SCHEMBL22090377 | 0.77 | LTA4H (0.44) | — | |
| SCHEMBL22090373 | 0.76 | HCRTR2 (0.39) | HCRTR2HCRTR1 | |
| SCHEMBL22090447 | 0.76 | HCRTR2 (0.39) | HCRTR2HCRTR1 | |
| SCHEMBL18805036 | 0.75 | HCRTR2 (0.44) | HCRTR2HCRTR1 | |
| SCHEMBL8399383 | 0.75 | LTA4H (0.52) | — | |
| SCHEMBL7374305 | 0.75 | LTA4H (0.52) | — | |
| SCHEMBL7374076 | 0.75 | LTA4H (0.52) | — | |
| SCHEMBL22102944 | 0.73 | HTR2A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12331029-B2 | Orexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| WO-2020120994-A1 | OREXIN 1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085056-A1 | OX1 RECEPTOR ANTAGONISTS | CNR1, CNR2, OPRM1 | HCRTR2 5/4885HCRTR1 4/4885 |
| US-12331029-B2 | Orexin 1 receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR2 2/4885HCRTR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.